Search Images Maps Play YouTube News Gmail Drive More »
Settings | Sign in

Hepatocellular carcinoma

Hepatocellular carcinoma A role for lncRNA in liver cancer

Nature.com - ‎Feb 9, 2016‎
New findings published in the Journal of Hepatology suggest a functional role for long non-coding RNAs (lncRNAs) in the development of hepatocellular carcinoma (HCC), which could ultimately aid prognosis and treatment of the disease. As the sixth most ...

Metastatic Hepatocellular Carcinoma (HCC) – Pipeline Review, H2 2015 by ReportBazzar

Medgadget.com (blog) - ‎Feb 11, 2016‎
This report provides comprehensive information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route ...
See realtime coverage

Study Challenges Use of Doxorubicin Beads for Hepatocellular Carcinoma

Cancer Therapy Advisor - ‎Feb 3, 2016‎
There appears to be no difference between chemoembolization using doxorubicin-eluting microspheres and embolization using microspheres alone in patients with hepatocellular carcinoma (HCC) undergoing hepatic artery embolization, a study published ...

Hepatocellular Carcinoma Market Report - Pipeline Review H2 2015 - Research and Markets

Business Wire (press release) - ‎Feb 3, 2016‎
This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration ...

Hepatocellular Carcinoma Pipeline Review, Market Growth, Segment, Trends and Forecast 2016 – 2020

Medgadget.com (blog) - ‎Feb 9, 2016‎
MRS145 “Hepatocellular CarcinomaPipeline Review, H2 2015“, provides an overview of the Hepatocellular Carcinoma 's therapeutic pipeline.

TSC2 mutations confer everolimus sensitivity in hepatocellular carcinomas

ScienceBlog.com (blog) - ‎Feb 5, 2016‎
Hepatocellular carcinomas (HCCs) are the third leading cause of cancer deaths globally; frequently diagnosed only in the advanced stages and aggressive in nature.

Human Validation Data Supporting Saronic Biotechnology's Lead Therapeutic SBI1997 Published in the Journal of ...

GlobeNewswire (press release) - ‎Feb 9, 2016‎
The research article, titled “Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on their Localization and Tumor Size” was accepted for publication in the Journal of Immunotherapy.

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

Dove Medical Press - ‎Feb 8, 2016‎
Purpose: The safety and efficacy of the combined use of sorafenib and yttrium-90 resin microspheres (Y90 RMS) to treat advanced hepatocellular carcinoma (HCC) is not well established. We determined the incidence of adverse events with this combination ...

Oxidation-Induced Degradable Nanogels for Iron Chelation

Nature.com - ‎Feb 12, 2016‎
Although DFO is one of the oldest FDA approved chelators for treatment of iron overload conditions, it possesses undesirable cytotoxic effects and has even been investigated as an anticancer drug in clinical trials for advanced hepatocellular carcinoma.

Hep C on Rise in New York City

MD Magazine - ‎Feb 12, 2016‎
Liver cancer (hepatocellular carcinoma) incidence and mortality rates have also climbed. In 1976 there were about 3 cases and six deaths per 100,0000 population in the city.

Clarified Role of Molecule Linked to Tumors Opens Door to New Cancer Therapies

Genetic Engineering & Biotechnology News - ‎Feb 10, 2016‎
According to Dr. Antonyuk, "Our work has provided a detailed insight into the synthesis of SAMe by this human enzyme and has opened the way to target it for therapeutic purposes for hepatocellular carcinoma and colon cancer." "Though the relationship ...
See realtime coverage

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

News-Medical.net - ‎Feb 9, 2016‎
Primary liver cancer, or hepatocellular carcinoma, is the sixth most prevalent type of cancer and third-leading cause of cancer-related deaths worldwide, according to the National Cancer Institute (NCI).
See realtime coverage

'Molecular movie' opens door to new cancer treatments

Phys.Org - ‎Feb 9, 2016‎
Dr Antonyuk, added: "Our work has provided a detailed insight into the synthesis of SAMe by this human enzyme and has opened the way to target it for therapeutic purposes for hepatocellular carcinoma and colon cancer." 'Crystallography captures ...

Increased Toxicity Confirmed for Thyroid Cancer Patients on Sorafenib

Cancer Network - ‎Feb 9, 2016‎
... in differentiated thyroid cancer reported thus far, it is noteworthy that the incidence rate of adverse effects due to sorafenib appears to be considerably higher in differentiated thyroid cancer patients than in renal cell carcinoma and ...

Hepatitis C Virus: A Clear Role for Pharmacists

Pharmacy Times - ‎Feb 11, 2016‎
Untreated, HCV progresses—over the course of 20 to 30 years in 75% to 85% of patients—to hepatocellular carcinoma, cirrhosis, and often, the need for liver transplantation.

A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity

Nature.com - ‎Feb 12, 2016‎
To identify genes that confer resistance to vorinostat, the vorinostat-sensitive HCT116 colon cancer cell line was serially passaged in the presence of vorinostat at apoptotic concentrations resulting in the development of stable vorinostat-resistant ...

A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-κB-dependent liver ...

Nature.com - ‎Feb 8, 2016‎
In this report, we have investigated the effect of this mutation on the response to liver injury and chemically induced hepatocellular carcinoma, both processes requiring NF-κB activity. We find that mutation of RelA Thr505 leads to an aberrant ...

Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.

UroToday - ‎Feb 11, 2016‎
There is a distinct increase in the rate of occurrence of adverse effects of sorafenib when used in differentiated thyroid cancer compared with renal and hepatocellular cancer. While many theoretical explanations have been proposed, the exact mechanism ...

LT candidates experience decreased physical function while waitlisted

Healio - ‎Feb 11, 2016‎
... 0.72; 95% CI, 0.62-0.84), chair stands (HR = 1.17; 95% CI, 1.09-1.25) and Short Physical Performance Battery less than 10 (HR = 1.45; 95% CI, 1.15-2.2), even after adjusting for MELD-Na, albumin, hepatocellular carcinoma and baseline physical function.

Incyte Discontinues Studies of Ruxolitinib to Treat Pancreatic Cancer; Shares Fall 15% in Pre Market (NASDAQ:INCY)

WallStreet.org - ‎Feb 11, 2016‎
... as well as in Phase I/II trial for non-small cell lung cancer and various tumor types; and capmatinib, which is in Phase I/II clinical trial for the treatment of solid tumors, as well as in Phase II trial for hepatocellular carcinoma and non-small ...
 -